long lost distant cousin of jd vance

damn there are thielbux behind every sv monstrosity

Maybe their idea is that publicly embarrassing oligarch boss of that company would be more effective in getting them to either use source code or buying a license

PSA that Nadella, Musk, saltman (and handful of other techfash) own dials that can bias their chatbots in any way they please. If you use chatbots for writing anything, they control how racist your output will be

firefox at minimum clears the very low bar of not exposing casual user to crypto

"People are planning 10 gigawatt data centers," Schmidt said. "Gives you a sense of how big this crisis is. Many people think that the energy demand for our industry will go from 3 percent to 99 percent of total generation

I reasoned that the former Google executive might have bought Relativity Space as a means to support the development of data centers in space.

absolutely not peak of bubble type bullshit, please give microsoft-sized theranos more money, nothing weird or stupid is happening there

last time i've seen someone wanting to put compute in orbit it was cryptobros trying to avoid everyone's jurisdiction, presumably to do some financial crimes there. turns out you can get away with this on earth, so it's unnecessary

no, all people here are 30-40 years old communist programmers from california

i'm convinced that rhyming slang is just 19th century coal mine brainrot. you cannot change my mind

decisive belarusian cultural victory

musk and thiel narrowly avoided death in 2000 car crash. can you imagine what could have been?

death of millions for profit - solid business practice, congratulations and see you again at next shareholder meeting

Derek Lowe has seen it coming years ago https://www.science.org/content/blog-post/lecanemab-and-alzheimer-s-more-data

But let’s stipulate that the result is real, for the sake of argument. That takes us into the very contentious question of real-world utility. As the NEJM paper says, “A definition of clinically meaningful effects in the primary end point of the CDR-SB score has not been established”. Clinicians are already disagreeing over whether the difference between lecanemab and placebo is something that would even be noticeable. That last link features a quote of Madhav Thambisetty, a neurologist at the National Institute on Aging: “From the perspective of a physician caring for Alzheimer’s patients, the difference between lecanemab and placebo is well below what is considered to be a clinically meaningful treatment effect”. This is not an uncommon take.

And that leads to question 3. A constant problem with these anti-amyloid antibody ideas is the complication of brain edema, an inflammation response that can be serious trouble. The term of the art is “amyloid-related imaging abnormalities with edema or effusions”, ARIA-E. This latest trial kept a constant watch for this, as well it should have, and any such trial also has to keep in mind the possibility of “functional unblinding” as any incidents develop. ARIA-E was noted in 0.8% of the treatment group (and in none of the placebo patients, naturally). Overall, adverse events that were enough to lead to patient discontinuation in the trial occurred in 6.9% of the treatment group and 2.9% of the placebo group. Most seriously, two patients in the treatment group have died from what could well be treatment-related vascular issues

There was also earlier anti-amyloid antibody that got approved despite showing no benefit at all https://www.science.org/content/blog-post/they-don-t-know